Medtronic PLC vs Veritone Inc — how do they compare? Medtronic PLC trades at $88.79 (market cap $112.24B), while Veritone Inc trades at $0.56 (market cap $59.46M). The key difference: Medtronic PLC is far larger — about 1887.7× Veritone Inc's market cap, and Medtronic PLC pays a 3.28% dividend while Veritone Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Medtronic PLC for 63 Days and Veritone Inc for 12 Days on average.
| MDT | VERI | |
|---|---|---|
Market Cap | $112.24B | $59.46M |
Volume | 105,663,236 | 15,523,164 |
Sector | Health | Technology |
52-Week High | $105.35 | $8.39 |
52-Week Low | $73.75 | $0.59 |
Typical Hold Time | 63 Days | 12 Days |
Enterprise Value | $131.58B | $94.86M |
Dividend Yield | 3.28% | — |
Signals from Pluang's Aura AI — not financial advice
Medtronic (MDT) trades at $88.48, up 3.47% today, with a bullish analyst consensus and a $97.80 price target. The stock shows strong fundamentals with revenue growth to $33.54B in 2025 and a net income margin of 13.93%. Recent earnings beats and a 49-year dividend growth streak highlight operational strength, though technical indicators signal a near-term bearish trend with key support at $87.
MDT presents a compelling long-term investment with stable profitability and dividend reliability, but faces risks from debt increases and competitive pressures. Upside potential exists if the company maintains earnings momentum and executes on growth initiatives, while volatility may persist due to market sentiment shifts.
Veritone (VERI) trades at $0.58, down 16% today, reflecting ongoing investor concerns despite some positive business developments. The stock shows bearish technical signals with moving averages indicating strong selling pressure, while fundamentals reveal significant challenges with a -117.5% net income margin and consistent quarterly losses. Recent news includes a $15 million equity offering and partnerships with ATP Media and ZeroEyes, though these are offset by ongoing securities litigation investigations.
The outlook remains challenging with persistent losses and negative cash flow from operations, though analyst consensus suggests substantial upside potential with a $3.75 price target. Key risks include the company's inability to achieve profitability, competitive pressures in AI solutions, and legal uncertainties. The stock presents high-risk speculation with potential for recovery if cost reductions and new partnerships drive meaningful revenue growth.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →Veritone is a leading provider of enterprise AI software and solutions, centered on its proprietary AI operating system, aiWARE™. The platform orchestrates a vast ecosystem of machine learning models to transform unstructured data—such as audio, video, and text—into actionable intelligence. Serving the media, entertainment, and public sectors, Veritone is a critical infrastructure partner for organizations looking to monetize data archives and operationalize AI at scale.
Read more on VERI →